Nasal Spray and Mouth Rinse Demonstrate Efficiency in Preventing COVID-19 and Other Infections
BMG Pharma's clinical trial has demonstrated positive results in the efficacy of BMG0705 Nasal Spray and BMG0703A Mouth Rinse as treatments for asymptomatic COVID-19 patients.
A clinical trial, conducted by BMG Pharma (a biopharmaceutical and B2B company), has demonstrated positive results in the efficacy of BMG0705 Nasal Spray and BMG0703A Mouth Rinse as treatments for asymptomatic COVID-19 patients, the company reported in a Aug. 2, 2021 press release.
The study, which included a total of 106 people, showed sufficient efficiency of the treatment with the nasal spray and mouth rinse versus placebo in preventing COVID-19—determined with a PCR test. The efficacy of the products is believed to be a result of the combined action of hydrogen peroxide and hyaluronic acid, which form protective barriers in the nasal mucosa and oral mucosa.
Based on the results, the company have suggested that the investigated active intervention may be effective at increasing the rate of negativization of a positive PCR swab test for SARS-CoV-2. However, further research is required to confirm the initial results in certain population subgroups.
Source: BMG Pharma
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
